| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| review article | Q7318358 |
| P356 | DOI | 10.1002/14651858.CD003133.PUB2 |
| P8608 | Fatcat ID | release_ljj7ctrwzndsnn2aiwfqd7iqle |
| P3181 | OpenCitations bibliographic resource ID | 3676530 |
| P698 | PubMed publication ID | 15106191 |
| P50 | author | Ritsuko Kakuma | Q63377851 |
| P2093 | author name string | F Ducharme | |
| Z Schwartz | |||
| G Hicks | |||
| P2860 | cites work | Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial | Q72998929 |
| The single and multiple dose pharmacokinetics of pranlukast in healthy volunteers | Q73018027 | ||
| Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group | Q73227877 | ||
| The effect of zafirlukast on repetitive exercise-induced bronchoconstriction: the possible role of leukotrienes in exercise-induced refractoriness | Q73251707 | ||
| Evaluation of efficacy of traditional Chinese medicines in the treatment of childhood bronchial asthma: clinical trial, immunological tests and animal study. Taiwan Asthma Study Group | Q73262974 | ||
| Efficacy of leukotriene receptor antagonist in bronchial hyperresponsiveness and hypersensitivity to analgesic in aspirin-intolerant asthma | Q73293741 | ||
| Effects of inhaled corticosteroids on bone | Q73532681 | ||
| Effects of 2 weeks of treatment with fluticasone propionate 100 mcg b.d. by comparison with zafirlukast 20 mg b.d. on bronchial hyper-responsiveness in patients with mild to moderate asthma | Q73542145 | ||
| Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist | Q73570827 | ||
| Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids | Q73681474 | ||
| A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group | Q74113179 | ||
| Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group | Q74471633 | ||
| The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma | Q74530454 | ||
| Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group | Q74643437 | ||
| Effect of inhaled corticosteroids on bones and growth | Q74737524 | ||
| Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction | Q74777695 | ||
| A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group | Q74812578 | ||
| Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects | Q77178375 | ||
| Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial | Q28192038 | ||
| Lung function improvement in asthma with a cysteinylleukotriene receptor antagonist | Q28322631 | ||
| Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease | Q28363645 | ||
| Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma | Q28369934 | ||
| The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children | Q28370742 | ||
| Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group | Q28371563 | ||
| Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis | Q28377209 | ||
| Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group | Q28377391 | ||
| Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma | Q28377400 | ||
| Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma | Q28377487 | ||
| Leukotriene receptor antagonists: efficacy and safety in children with asthma | Q31420368 | ||
| Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis | Q31894371 | ||
| Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years | Q31894426 | ||
| Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients | Q33627353 | ||
| Publication bias in meta-analysis: its causes and consequences | Q33870662 | ||
| Tolerability of montelukast. | Q33878233 | ||
| What is new since the last (1999) Canadian Asthma Consensus Guidelines? | Q34255578 | ||
| Desloratadine: A new, nonsedating, oral antihistamine | Q34514592 | ||
| A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy | Q34750109 | ||
| Scheduled follow-up after a pediatric emergency department visit for asthma: a randomized trial | Q35075561 | ||
| Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients | Q35533728 | ||
| Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma | Q35535752 | ||
| Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma | Q35535801 | ||
| Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids | Q35563114 | ||
| Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers | Q35563630 | ||
| Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma | Q35563656 | ||
| Effect of intravenous corticosteroid on ex vivo leukotriene generation by blood leucocytes of normal and asthmatic patients | Q35573060 | ||
| Estimation of a common effect parameter from sparse follow-up data | Q36496002 | ||
| Should unpublished data be included in meta-analyses? Current convictions and controversies | Q36782679 | ||
| Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. | Q53983069 | ||
| Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children. | Q54043857 | ||
| NO in Exhaled Air of Asthmatic Children Is Reduced by the Leukotriene Receptor Antagonist Montelukast | Q57638323 | ||
| Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma | Q68121522 | ||
| The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air | Q68613879 | ||
| Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma | Q70726803 | ||
| Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects | Q71723668 | ||
| Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group | Q71823499 | ||
| Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma | Q72032630 | ||
| Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078 | Q72047221 | ||
| Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma | Q72123963 | ||
| Glucocorticoid-induced attenuation of mucosal exudation of fibrinogen and bradykinins in seasonal allergic rhinitis | Q72486543 | ||
| The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma | Q72605042 | ||
| Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma | Q39401447 | ||
| Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis | Q39406077 | ||
| Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older | Q40700694 | ||
| International consensus on the management of pediatric asthma: a summary statement | Q40897088 | ||
| Long-, intermediate- and short-term growth studies in asthmatic children treated with inhaled glucocorticosteroids | Q41050667 | ||
| Glucocorticoids and growth in asthmatic children | Q41072746 | ||
| A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma | Q41273463 | ||
| Effect of RG 12525, an oral leukotriene D4 antagonist, on the airway response to inhaled leukotriene D4 in subjects with mild asthma | Q42126419 | ||
| Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group | Q42284265 | ||
| Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. | Q42286335 | ||
| Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. | Q42537754 | ||
| Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group | Q42546418 | ||
| Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. | Q42551235 | ||
| Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group | Q42556993 | ||
| Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold dry air. | Q43043791 | ||
| Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids | Q43505948 | ||
| Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy | Q43510996 | ||
| Effects of pranlukast, a leukotriene receptor antagonist, on airway inflammation in mild asthmatics | Q43546448 | ||
| Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial | Q43551417 | ||
| Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids | Q43570673 | ||
| Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. | Q43601132 | ||
| Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol | Q43616375 | ||
| Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction. | Q43655204 | ||
| Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial | Q43662390 | ||
| Efficacy and safety of long-term treatment of asthmatic patients with pranlukast, a cysteinyl-leukotriene-receptor antagonist: four-year followup study | Q43690018 | ||
| Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma | Q43722886 | ||
| A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma | Q43724406 | ||
| Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone | Q43732329 | ||
| Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis | Q43784463 | ||
| Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma | Q43898828 | ||
| A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. | Q43944876 | ||
| Safety, tolerability and acceptability of two dry powder inhalers in the administration of budesonide in steroid-treated asthmatic patients | Q43986147 | ||
| Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma | Q44048591 | ||
| Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma | Q44054406 | ||
| Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma | Q44061851 | ||
| Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients | Q44110888 | ||
| Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children | Q44162562 | ||
| Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma | Q44180365 | ||
| Effects of montelukast and budesonide on airway responses and airway inflammation in asthma | Q44196721 | ||
| Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma | Q44227359 | ||
| Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. | Q44232436 | ||
| Effects of montelukast and beclomethasone on airway function and asthma control | Q44237810 | ||
| Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. | Q44247874 | ||
| Effect of the addition of montelukast to inhaled fluticasone propionate on airway inflammation | Q44248031 | ||
| Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture | Q44290303 | ||
| Effects of oral montelukast on airway function in acute asthma | Q44432850 | ||
| One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma | Q44482599 | ||
| MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human | Q49122118 | ||
| Effectiveness of montelukast versus budesonide on quality of life and bronchial reactivity in subjects with mild-persistent asthma. | Q51030309 | ||
| Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial). | Q53516366 | ||
| Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. | Q53573791 | ||
| P433 | issue | 2 | |
| P921 | main subject | asthma | Q35869 |
| P304 | page(s) | CD003133 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma |
| Q24794527 | Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review |
| Q38903489 | Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma |
| Q24197585 | Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma |
| Q24200999 | Addition to inhaled corticosteroids of long-acting beta 2-agonists versus anti-leukotrienes for chronic asthma |
| Q33766956 | An integrative review of systematic reviews related to the management of breathlessness in respiratory illnesses |
| Q36298174 | Asthma and athletes: therapy to compete |
| Q36436434 | Asthma control in adults |
| Q36027085 | Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults |
| Q33836132 | Canadian Thoracic Society Asthma Management Continuum--2010 Consensus Summary for children six years of age and over, and adults |
| Q38219526 | Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis |
| Q101573965 | Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management |
| Q36561046 | Cost effectiveness of leukotriene modifiers in adults with asthma |
| Q34620134 | Current recommendations for the treatment of mild asthma |
| Q28392274 | Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations |
| Q33664193 | Inhaled Corticosteroids |
| Q34995731 | Inhaled corticosteroids in childhood asthma: the story continues |
| Q24197736 | Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children |
| Q26769046 | Pharmacotherapy in the management of asthma in the elderly: a review of clinical studies |
| Q33424090 | Rates of asthma attacks in patients with previously inadequately controlled mild asthma treated in clinical practice with combination drug therapy: an exploratory post-hoc analysis. |
| Q36067978 | Recent developments in asthma management |
| Q79245147 | Treatment with 400 microg of inhaled budesonide vs 200 microg of inhaled budesonide and oral montelukast in children with moderate persistent asthma: randomized controlled trial |
Search more.